DanielJWeisdorfMD

Oncology • Minneapolis, MN

Professor, Medicine, University of Minnesota Medical School

Join to view full profile

Dr. Weisdorf is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Weisdorf's full profile

Already have an account?

Office
516 Delaware Street Se
MMC 480, PWB 14-110
Minneapolis, MN 55455
Phone+1 612-624-3101

Fax+1 612-625-6919
Is this information wrong?

Education & Training

University of MinnesotaFellowship, Hematology and Medical Oncology, 1978 - 1981
Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1975 - 1978
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1975

Certifications & Licensure

ND State Medical License 2022 - 2025
MN State Medical License 1978 - 2024
IL State Medical License 1976 - 1987
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Super Doctor SuperDoctors.com

Clinical Trials

Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma Start of enrollment: 2000 Aug 01
Completed
Phase 2
Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma Start of enrollment: 2000 Aug 01
Terminated
Phase 2
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease Start of enrollment: 2000 Jan 01
Withdrawn
Phase 2
Blood and Marrow Transplant Clinical Research Network Start of enrollment: 2001 Sep 01
Completed
Not Applicable
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
Completed
Phase 3
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Start of enrollment: 2003 Dec 01
Completed
Phase 3
Stem Cell Transplant for Hematological Malignancy Start of enrollment: 2001 Oct 01
Terminated
Not Applicable
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) Start of enrollment: 2005 Sep 01
Completed
Phase 2
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease Start of enrollment: 2005 Jul 01
Terminated
Phase 2
Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Start of enrollment: 1999 Oct 06
Completed
Phase 2
Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2006 Jul 26
Terminated
Phase 2, Phase 3
Stem Cell Related Donor Safety Study Start of enrollment: 2010 Jan 01
Completed
Selecting a Favorable KIR Donor in Unrelated HCT for AML Start of enrollment: 2011 Jun 01
Completed
Not Applicable
Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS Start of enrollment: 2018 Aug 13
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Pre-frailty after blood or marrow transplantation and the risk of subsequent mortality.
Nora Balas, Joshua S Richman, Wendy Landier, Sadeep Shrestha, Katia J Bruxvoort, Lindsey Hageman, Qingrui Meng, Elizabeth Ross, Alysia Bosworth, F Lennie Wong, Ravi Bh...> ;Leukemia. 2024 Apr 5
Body composition and late-occurring chronic health conditions after autologous stem cell transplantation for lymphoma.
Christian Harmon, Wendy Landier, Yanjun Chen, Jessica Wu, Lindsey Hageman, Nora Balas, Liton Francisco, Alysia Bosworth, Smith Giri, Daniel J Weisdorf, Stephen J Forma...> ;Cancer. 2024 Apr 5
Long- and short-term effects of fecal microbiota transplantation on antibiotic resistance genes: results from a randomized placebo-controlled trial.
Armin Rashidi, Maryam Ebadi, Tauseef Ur Rehman, Heba Elhusseini, David Kazadi, Hossam Halaweish, Mohammad H Khan, Andrea Hoeschen, Qing Cao, Xianghua Luo, Amanda J Kab...> ;Gut Microbes. 2024 Mar 13
Treatment-Sensitive and Treatment-Dependent Chronic Graft-versus-Host Disease Yield Superior Failure-Free and Overall Survival Compared to Treatment-Resistant Chronic ...
Shannon Herzog, Ryan Shanley, Shernan G Holtan, Margaret L MacMillan, Daniel J Weisdorf, Najla El Jurdi> ;Transplantation and Cellular Therapy. 2024 Mar 11
Late morbidity and mortality after autologous blood or marrow transplantation for lymphoma in children, adolescents and young adults-a BMTSS report.
Anna Sällfors Holmqvist, Qingrui Meng, Chen Dai, Lindsey Hageman, Wendy Landier, Jessica Wu, Liton F Francisco, Elizabeth Schlichting Ross, Nora Balas, Alysia Bosworth...> ;Leukemia. 2024 Mar 1
Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML.
Joshua A Fein, Roni Shouval, Elizabeth Krieger, Stephen R Spellman, Tao Wang, Henning Baldauf, Katharina Fleischhauer, Nicolaus Kröger, Mary Horowitz, Martin Maiers, J...> ;Blood Advances. 2024 Feb 13
Impact of melphalan day -1 vs day -2 on outcomes after autologous stem cell transplant for multiple myeloma.
Aimee Merino, Ryan Shanley, Faridullah Rashid, Jenna Langer, Sarah Tu, Najla El Jurdi, John Rogosheske, Kirollos Hanna, Todd DeFor, Michelle Dolan, Murali Janakiram, D...> ;Frontiers in Immunology. 2024 Jan 1
The best GVHD prophylaxis: Or at least progress towards finding it.
El Jurdi, N., Weisdorf, D., Holtan, S.> ;Best Practice & Research. Clinical Haematology. 2023 Dec 1
1 citations
Gene-Level Analysis of Anthracycline-Induced Cardiomyopathy in Cancer Survivors: A Report From COG-ALTE03N1, BMTSS, and CCSS.
Sharafeldin, N., Zhou, L., Singh, P., Crossman, D., Wang, X., Hageman, L., Landier, W., Blanco, J., Burridge, P., Sapkota, Y., Yasui, Y., Armstrong, G., Robison, L., H...> ;JACC. Cardiooncology. 2023 Dec 1
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis.
Abid, M. B., Hemant S Murthy, Mei-Jie Zhang, Karen Chen, Sairah Ahmed, Uday Deotare, Siddhartha Ganguly, Ankit Kansagra, Fotios V Michelis, Taiga Nishihori, Mrinal Pat...> ;Blood Advances. 2023 Nov 28
Health care utilization by long-term survivors of blood or marrow transplantation-A Bone Marrow Transplant Survivor Study report.
Marian M Oliver, Qingrui Meng, Lindsey Hageman, Wendy Landier, Nora Balas, Elizabeth Ross, Liton Francisco, Alysia Bosworth, Hok Sreng Te, F Lennie Wong, Ravi Bhatia, ...> ;Cancer. 2024 Mar 1
Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age.
Rima M Saliba, Christopher G Kanakry, Shahinaz Gadalla, Partow Kebriaei, Katayoun Rezvani, Richard E Champlin, Elizabeth J Shpall, Daniel Weisdorf, Rohtesh S Mehta> ;American Journal of Hematology. 2024 Jan 1
1 citations
Access to CAR T-cell therapy: Focus on diversity, equity and inclusion.
Maria S Odstrcil, Catherine J Lee, Catherine Sobieski, Daniel Weisdorf, Daniel Couriel> ;Blood Reviews. 2024 Jan 1
1 citations
Potential of Fecal Microbiota Transplantation to Prevent Acute GVHD: Analysis from a Phase II Trial.
Armin Rashidi, Maryam Ebadi, Tauseef Ur Rehman, Heba Elhusseini, David Kazadi, Hossam Halaweish, Mohammad H Khan, Andrea Hoeschen, Qing Cao, Xianghua Luo, Amanda J Kab...> ;Clinical Cancer Research. 2023 Dec 1
1 citations
Amphiregulin as monitoring biomarker for life-threatening acute graft-versushost disease: secondary analysis of two prospective clinical trials.
Shernan G Holtan, Najla El Jurdi, Armin Rashidi, Brian C Betts, Connor Demorest, John P Galvin, Margaret L MacMillan, Daniel J Weisdorf, Angela Panoskaltsis-Mortari, M...> ;Haematologica. 2023 Sep 14
Risky health behaviors and subsequent late mortality after blood or marrow transplantation: a BMTSS report.
Nora Balas, Joshua Richman, Wendy Landier, Sadeep Shrestha, Katia J Bruxvoort, Lindsey Hageman, Qingrui Meng, Elizabeth Ross, Alysia Bosworth, Hok Sreng Te, F Lennie W...> ;Blood Advances. 2023 Nov 28
1 citations
Pre-transplant and longitudinal changes in faecal microbiome characteristics are associated with subsequent development of chronic graft-versus-host disease.
Najla El Jurdi, Shernan G Holtan, Andrea Hoeschen, Jessica Velguth, Benjamin Hillmann, Brian C Betts, Margaret L MacMillan, Daniel J Weisdorf, Alexander Khoruts, Armin...> ;British Journal of Haematology. 2023 Oct 1
1 citations
Prediction of Coronary Heart Disease Events in Blood or Marrow Transplantation Recipients.
Radhika Gangaraju, Yanjun Chen, Lindsey Hageman, Wendy Landier, Nora Balas, Elizabeth Ross, Liton Francisco, Alysia Bosworth, Hok Sreng Te, F Lennie Wong, Daniel J Wei...> ;JACC. Cardiooncology. 2023 Aug 1
Risk of COVID-19 infection in long-term survivors of blood or marrow transplantation: a BMTSS report.
Johnston, E., Meng, Q., Hageman, L., Wu, J., Ross, E., Lim, S., Balas, N., Bosworth, A., Te, H., Francisco, L., Bhatia, R., Forman, S., Wong, F., Armenian, S., Weisdor...> ;Blood Advances. 2023 Jun 27
3 citations
Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.
Najla El Jurdi, Alex Hoover, Daniel O'Leary, Qing Cao, Ashish Gupta, Christen Ebens, Joseph E Maakaron, Brian C Betts, Armin Rashidi, Mark B Juckett, Troy Lund, Veroni...> ;Transplantation and Cellular Therapy. 2023 Sep 1
Radiation hazards of the Ukraine nuclear power plants: how can international blood and marrow stem cell transplant societies help?
Shahrukh K Hashmi, Ray C Powles, David Ma, Ibrahim N Muhsen, Mahmoud Aljurf, Dietger Niederwieser, Daniel J Weisdorf, Mickey B C Koh, Hildegard Greinix> ;Annals of Hematology. 2024 Apr 1
2 citations
Phase II, Open-Label Clinical Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-Threatening Acute Graft-versus-Host Disease.
Shernan G Holtan, Andrea Hoeschen, Qing Cao, Celalettin Ustun, Brian C Betts, Najla El Jurdi, Joseph Maakaron, Armin Rashidi, Jeffrey S Miller, John E Wagner, Bruce R ...> ;Transplantation and Cellular Therapy. 2023 Aug 1
3 citations
Randomized Double-Blind Phase II Trial of Fecal Microbiota Transplantation Versus Placebo in Allogeneic Hematopoietic Cell Transplantation and AML.
Armin Rashidi, Maryam Ebadi, Tauseef Ur Rehman, Heba Elhusseini, David Kazadi, Hossam Halaweish, Mohammad H Khan, Andrea Hoeschen, Qing Cao, Xianghua Luo, Amanda J Kab...> ;Journal of Clinical Oncology. 2023 Dec 1
2 citations
Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes.
Shannon Herzog, Daniel J Weisdorf, Ryan Shanley, Ahmad Rayes, Shernan G Holtan, Jo-Anne Young, Margaret L MacMillan, Najla El Jurdi> ;Blood Advances. 2023 Jul 25
How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?
Mark Juckett, Christopher Dandoy, Zachariah DeFilipp, Tamila L Kindwall-Keller, Stephen R Spellman, Celalettin Ustun, Bryce M Waldman, Daniel J Weisdorf, William A Woo...> ;Blood Reviews. 2023 Jul 1
Join now to see all

Journal Articles

Amphiregulin in Intestinal Acute Graft-Versus-Host Disease: A Possible Diagnostic and Prognostic Aid
Brittney Schultz, Bruce R Blazar, Daniel J Weisdorf, Shernan G Holtan, Alexander Khoruts, Armin Rashidi, Margaret L MacMillan, Khalid Amin, Byron P Vaughn, Nature
Related Peripheral Blood Stem Cell Donors Experience More Severe Symptoms and Less Complete Recovery at 1-Year Compared to Unrelated Donors
Parameswaran N Hari, David A Jacobsohn, Joseph P McGuirk, Mary M Horowitz, Walter Longo, Thomas Spitzer, Daniel J Weisdorf, Shahram Mori, David C Delgado, Marcie L Ric..., Haematologica
Narrowing the Gap for Hematopoietic Stem Cell Transplantation in the East-Mediterranean/African Region: Comparison with Global HSCT Indications and Trends
Marcelo Pasquini, Daniel Weisdorf, Nature
Upper Gastrointestinal Acute Graft-Versus-Host Disease Adds Minimal Prognostic Value in Isolation or with Other Graft-Versus-Host Disease Symptoms as Currently Diagnos...
Margaret MacMillan, Sophie Paczesny, Ran Reshef, Daniel Weisdorf, Haematologica
Diffuse Alveolar Hemorrhage Is Most Often Fatal and Is Affected by Graft Source, Conditioning Regiment Toxicity, and Engraftment Kinetics
Erhan H Dincer, Erica D Warlick, Margaret L MacMillan, Patrick Arndt, Daniel J Weisdorf, Nelli Bejanyan, Claudio G Brunstein, Celalettin Ustun, Aleksandr Lazaryan, Ver..., Haematologica
Recipient Single Nucleotide Polymorphisms in Paneth Cell Antimicrobial Peptide Genes and Acute Graft‐Versus‐Host Disease: Analysis of BMT CTN‐0201 and ‐0901 Samples
Armin Rashidi, Edmund K Waller, Bharat Thyagarajan, Claudio Anasetti, Daniel J Weisdorf, Bart L Scott, Bruce R Blazar, British Journal of Haematology
A Phase II/III Randomized, Multicenter Trial of Prednisone /Sirolimus vs Prednisone/Sirolimus/Calcineurin Inhibitor for Treatment of Chronic Graft-Versus-Host Disease:...
Amin M Alousi, Mukta Arora, Luciano J Costa, Aleksandr Lazaryan, Daniel J Weisdorf, Sunil Abhyankar, Eneida R Nemecek, Haematologica
Late Mortality After Allogeneic Blood or Marrow Transplantation in Childhood for Leukemia: A Report from the Blood or Marrow Transplant Survivor Study-2
Stephen J Forman, Daniel J Weisdorf, Donna Salzman, Mukta Arora, Saro H Armenian, Nature
Join now to see all

Abstracts/Posters

High Risk of Relapse with Intermediate Dose Cytarabine for Consolidation in Young Favorable Risk AML Patients Following Induction with 7+3
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disea...
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Pre-Transplant Serum Claudin-3 Predicts Intestinal Graft-Versus-Host Disease and Non-Relapse Mortality Risk after Allogeneic Hematopoietic Cell Transplantation
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Longitudinal Trajectory of Frailty in Blood or Marrow Transplant (BMT) Survivors _ a BMT Survivor Study (BMTSS)
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopo...
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
One and Half Million Hematopoietic Stem Cell Transplants (HSCT). Dissemination, Trends and Potential to Improve Activity By Telemedicine from the Worldwide Network for...
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) _ Long-Term Follow-up of a Phase 2a Study (KD025-208)
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young ...
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A...
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Stroke Risk in Blood or Marrow Transplant (BMT) Survivors _ a Report from the BMT Survivor Study (BMTSS)
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Ver...
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Global State of Hematopoietic Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Datab...
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Burden of Long-Term Morbidity Borne By Survivors of Acute Myeloid Leukemia (AML) Treated with Blood or Marrow Transplantation (BMT) _ a Report from the BMT Survivor St...
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Burden of Morbidity Borne By Survivors of Multiple Myeloma (MM) Treated with Autologous Blood or Marrow Transplant (BMT) - Results of the BMT Survivor Study (BMTSS)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Validation of Minnesota Acute Gvhd Risk Score and Identification of New Factors Associated with Initial Response to Steroids: Not All Gvhd Is Created Equal
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Grant Support

Enhancing The Safety Of Allogeneic TransplantationNational Heart, Lung, And Blood Institute2011
Clinical Transplantation Exploiting NK Cell ActivityNational Cancer Institute2005–2011
Enhanced GVHD Prophylaxis In Allogeneic Stem Cell TransplantationNational Heart, Lung, And Blood Institute2006–2010
Mt2003-23:Non-Myeloblative Haploidentical HSCT With NK Cell Infusions In High RINational Center For Research Resources2007
Non-Myeloblative Haploidentical HSCT With NK Cell Infusions In High Risk MyeloidNational Center For Research Resources2006
Enhanced GVHD Prophylaxis In Allogeneic Stem Cell Trans*National Heart, Lung, And Blood Institute2002–2005
Enhanced GVHD Prophylaxis An Allogenein Stem Cell Trans*National Heart, Lung, And Blood Institute2001
Posttransplant Immunotherapy Of Lymphoma With IL2National Cancer Institute1998–1999
Stem Cell Transplantation For Multiple MyelomaNational Cancer Institute1996–1999
Autologous Bone Marrow Transplantation For Lymphoma--ImmunotherapyNational Cancer Institute1996–1997